Madrigal Pharmaceuticals, Inc.
Pays vs peer median
×1.38
+38% premium
Sample
3
low confidence
Last refreshed
2026-04-13
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| metabolic | ×1.38 | 3 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| preclinical | ×1.38 | 3 |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | — | Suzhou Ribo Life Science Co. Ltd. and Ribocure Pharmaceuticals AB | Metabolic dysfunction-associated steatohepatitis (MASH) | preclinical | $60M | $4.5B |
| 2026 | — | Ribo Life Science Co. Ltd. | metabolic dysfunction-associated steatohepatitis (MASH) | preclinical | — | $4.4B |
| 2026 | — | Suzhou Ribo Life Sciences | MASH (metabolic associated steatohepatitis) | preclinical | $60M | $4.5B |
| 2025 | SYH2086 | CSPC | MASH | preclinical | $120M | $2.1B |
| 2025 | SYH2086 | CSPC Pharmaceutical | MASH | preclinical | $120M | $2.1B |
| 2025 | siRNA MASH portfolio | Ribo Life Science | MASH/NASH | preclinical | $60M | $4.4B |
How this is computed
For each Madrigal Pharmaceuticals, Inc. deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 1.384, clamped to [0.7, 1.5].